99764-63-3

Upstream product

• 123-75-1 pyrrolidine 
• 442688-36-0 1-[N-(Tert-butoxycarbonyl)piperidin-4yl]-3-(3-chloropropyl)-1,3-dihydrobenzimidazol-2-one 
• 112883-29-1 N-Fmoc-Tyr-OH 
• 281235-00-5 tert-butyl 4-(4-(methoxycarbonyl)phenoxy)piperidine-1-carboxylate 
• 121-44-8 triethylamine 
• 167215-80-7 N-[4-(Carboxy)benzyl]-N,N'-bis[(2-triphenylmethyl-thio)ethyl]glycinamide N-hydroxysuccinimide ester 
• 15788-16-6 5-benzimidazolecarboxylic acid 
• 558-30-5 2-methyl-1,2-epoxypropane 
• 109-01-3 1-methyl-piperazine 
• 107-45-9 tert-Octylamine 
• 162046-54-0 4-((5-benzimidazolylcarbonyl)amino)phenylacetic acid 
• 35386-24-4 1-(2-Methoxyphenyl)piperazine 
• 7732-18-5 water 
• 75-05-8 acetonitrile 

Downstream Products

• 548770-22-5 methyl-phenyl-carbamic acid 4-{2-[(pyridine-3-carbonyl)-amino]-ethyl}-phenyl ester 
• 549510-99-8 methyl-phenyl-carbamic acid 4-{2-[4-(4-methyl-piperazin-1-yl)-benzoylamino]-ethyl}-phenyl ester 
• 548770-31-6 methyl-phenyl-carbamic acid 4-{2-[(1-methyl-piperidine-4-carbonyl)-amino]-ethyl}-phenyl ester 
• 548770-23-6 methyl-phenyl-carbamic acid 4-[2-(2-dimethylamino-acetylamino)-ethyl]-phenyl ester 
• 548770-38-3 3,3-Dimethyl-4-{2-[4-(methyl-phenyl-carbamoyloxy)-phenyl]-ethylcarbamoyl}-butyric acid 
• 548770-51-0 methyl-phenyl-carbamic acid 4-[2-(4,4-dimethyl-2,6-dioxo-piperidin-1-yl)-ethyl]-phenyl ester 
• 548770-29-2 methyl-phenyl-carbamic acid 2-[4-(2-pyrrolidin-1-yl-ethoxy)-benzenesulfonyl]-1,2,3,4-tetrahydro-isoquinolin-7-yl ester 
• 503169-69-5 methyl (3S,4S)-4-({4-[(2-methyl-4-quinolinyl)methyl]benzoyl}amino)-1-(2-propynyl)-3-pyrrolidinecarboxylate 
• 477583-12-3 N-[1-(2,5-dioxo-4-imidazolidinyl)cyclopentyl]-4-[(2-methyl-4-quinolinyl)methoxy]benzamide 
• 202819-52-1 (RS)-3-amino-2-oxo-1-benzyl-azepine 
• 223490-48-0 (3-{[(4-Pyrazol-1-yl-benzyl)-(thiazole-2-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid hydrochloride salt 
• 333995-98-5 1-Acetyl-N-(3-chlorophenyl)-N-[3-[4-(2-benzthiazolylthio)-1-piperidinyl]propyl]-4-piperidinecarboxamide Hydrochloride 
• 224445-42-5 [(4-{(S)-2-Acetylamino-2-[(S)-1-(3-carbamoyl-4-cyclohexylmethoxy-phenyl)-ethylcarbamoyl]-ethyl}-phenyl)-(diethoxy-phosphoryl)-methyl]-phosphonic Acid Diethyl Ester 

Relevant academic research and scientific papers

TEMPLATES FOR NUCLEATION AND PROPAGATION OF PEPTIDE SECONDARY STRUCTURE

Compounds having the Formula I and pharmaceutically acceptable salts thereof are provided in which the variables are described herein. Methods of making the compounds of Formula I are also disclosed.

NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS

The present invention relates to novel lipopeptide compounds, pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial compounds. The compounds of the invention are particularly useful against a variety of bacte

Spirocyclic nitriles as protease inhibitors

The invention relates to substituted carbo- and heterocyclic spiro compounds of the formula Ia which inhibit thiol proteases, to processes for their preparation and to the use thereof as medicaments.

Process for preparing an intermediate to opioid receptor antagonists

The invention provides an efficient method for preparing 3-endo-(8-azabicyclo[3.2.1]oct-3-yl)benzamide by hydrogenation, under controlled conditions, of an amino-protected 3-(8-azabicyclo[3.2.1 ]oct-2-en-3-yl)benzamide intermediate in which the amino-prot

Substituted Aminothiazole Prodrugs of Compounds with Anti-HCV Activity

The invention provides amino-substituted aminothiazole compounds of Formula I and Formula II where A is a group of the formula: and the variables X, Y, R, and R1 to R7 are described herein. These compounds are prodrugs of compounds useful as inhibitors of viral replication. Compositions containing such compounds, and methods of treating viral infections with these compounds, as well as to processes and intermediates useful for preparing such compounds are also provided by the invention.

Methods for detecting nucleic acid variations

The invention provides methods and diagnostic test kits for detecting target nucleic acid sequence variations in a sample. In particular, a plurality of oligonucleotide probe sets is provided. Each set has a target specific portion and a barcode. The target specific portions of the probes are suitable for ligation together when hybridized adjacent to one another on a corresponding target polynucleotide. The ligated product contains a barcode that binds to a probe attached to a substrate and hence facilitate the capture of the ligated product on the solid support. Detection is carried out with a gold nanoparticle-attached barcode that hybridizes with the barcode on the ligated product.

Method and compositions for identifying anti-HIV therapeutic compounds

Methods are provided for identifying anti-HIV therapeutic compounds substituted with carboxyl ester or phosphonate ester groups. Libraries of such compounds are screened optionally using the novel enzyme GS-7340 Ester Hydrolase. Compositions and methods relating to GS-7340 Ester Hydrolase also are provided.

Combination therapy with CHK1 inhibitors

Compounds of Structure I, and salts, tautomers, stereoisomers, and mixtures thereof may be used in methods of inhibiting checkpoint kinase 1 in subjects, in methods for inducing cell cycle progression, and in methods for increasing apoptosis in cells. Such compounds may be used to prepare pharmaceutical compositions and may be used in conjunction with DNA damaging agents.

Inhibition of FGFR3 and treatment of multiple myeloma

Methods of inhibiting fibroblast growth factor receptor 3 and treating various conditions mediated by fibroblast growth factor receptor 3 are provided that include administering to a subject a compound of Structure I, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I have the following structure where and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting fibroblast growth factor receptor 3 and for use in treating conditions mediated by fibroblast growth factor receptor 3 such as multiple myeloma.

Tetrahydroquinoline analogues as muscarinic agonists

The present invention relates to tetrahydroquinoline compounds as muscarinic receptor agonists; compositions comprising the same; methods of inhibiting an activity of a muscarinic receptor with said compounds; methods of treating a disease condition associated with a muscarinic receptor using said compounds; and methods for identifying a subject suitable for treatment using said compounds.